A POTENTIAL ANALGESIC TARGET IN A NOVEL CLINICALLY-RELEVANT NEUROPATHIC PAIN PATHWAY.
Grant number: 1099930 | Funding period: 2016 - 2018
Persistent pain arising from tissue damage, to nerves, muscles or joints for example, is devastating for patients and a huge social and economic burden. This work will investigate one of the pathways that goes awry after sensory nerves are damaged. These experiments will also test whether a drug being developed to treat Alzheimer's disease is effective at blocking the persistent nerve hypersensitivity that sometimes develops after injury.
Related publications (2)
The Sez6 Family Inhibits Complement by Facilitating Factor I Cleavage of C3b and Accelerating the Decay of C3 Convertases
Wen Q Qiu, Shaopeiwen Luo, Stefanie A Ma, Priyanka Saminathan, Herman Li, Jenny M Gunnersen, Harris A Gelbard, Jennetta W Hammond
The Sez6 family consists of Sez6, Sez6L, and Sez6L2. Its members are expressed throughout the brain and have been shown to influen..
Beta-Site Amyloid Precursor Protein Cleaving Enzyme 1 Inhibition Impairs Synaptic Plasticity via Seizure Protein 6
Kaichuan Zhu, Xianyuan Xiang, Severin Filser, Petar Marinkovic, Mario M Dorostkar, Sophie Crux, Ulf Neumann, Derya R Shimshek, Gerhard Rammes, Christian Haass, Stefan F Lichtenthaler, Jenny M Gunnersen, Jochen Herms
BACKGROUND: Beta-site amyloid precursor protein cleaving enzyme 1 (BACE1) is a promising drug target for the treatment of Alzheime..